Is Kazia Therapeutics Stock a good buy in 2025, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: KZIA) stock is to Strong Buy KZIA stock.
Out of 1 analyst, 1 (100%) are recommending KZIA as a Strong Buy, 0 (0%) are recommending KZIA as a Buy, 0 (0%) are recommending KZIA as a Hold, 0 (0%) are recommending KZIA as a Sell, and 0 (0%) are recommending KZIA as a Strong Sell.
What is KZIA's earnings growth forecast for 2025-2025?
(NASDAQ: KZIA) Kazia Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 19.72%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 24.9%.
Kazia Therapeutics's earnings in 2025 is -$17,388,311.
In 2025, KZIA is forecast to generate -$1,098,407,587 in earnings, with the lowest earnings forecast at -$1,098,407,587 and the highest earnings forecast at -$1,098,407,587.
What is KZIA's forecast return on equity (ROE) for 2025-2027?
(NASDAQ: KZIA) forecast ROE is 0%, which is considered weak.
What is KZIA's Price Target?
According to 1 Wall Street analyst that have issued a 1 year KZIA price target, the average KZIA price target is $3.00, with the highest KZIA stock price forecast at $3.00 and the lowest KZIA stock price forecast at $3.00.
The Wall Street analyst predicted that Kazia Therapeutics's share price could reach $3.00 by Feb 6, 2026. The average Kazia Therapeutics stock price prediction forecasts a potential upside of 201.51% from the current KZIA share price of $1.00.
What is KZIA's Earnings Per Share (EPS) forecast for 2025-2025?
(NASDAQ: KZIA) Kazia Therapeutics's current Earnings Per Share (EPS) is -$6.60. In 2025, KZIA's EPS is forecast to hit -$3.30 (min: -$3.30, max: -$3.30).
What is KZIA's forecast return on assets (ROA) for 2025-2027?
(NASDAQ: KZIA) forecast ROA is 0%, which is lower than the forecast US Biotechnology industry average of 23.25%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.